Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm
Several studies show that the immunosuppressive drugs targeting the interleukin-6 (IL-6) receptor, including tocilizumab, ameliorate lethal inflammatory responses in COVID-19 patients infected with SARS-CoV-2. Here, by employing single-cell analysis of the immune cell composition of two severe-stage COVID-19 patients prior to and following tocilizumab-induced remission, we identify a monocyte subpopulation that contributes to the inflammatory cytokine storms. Furthermore, although tocilizumab treatment attenuates the inflammation, immune cells, including plasma B cells and CD8+ T cells, still exhibit robust humoral and cellular antiviral immune responses. Thus, in addition to providing a high-dimensional dataset on the immune cell distribution at multiple stages of the COVID-19, our work also provides insights into the therapeutic effects of tocilizumab, and identifies potential target cell populations for treating COVID-19-related cytokine storms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Nature communications - 11(2020), 1 vom: 06. Aug., Seite 3924 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guo, Chuang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 25.08.2020 Date Revised 29.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-020-17834-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313397090 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313397090 | ||
| 003 | DE-627 | ||
| 005 | 20240329234055.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-020-17834-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1354.xml |
| 035 | |a (DE-627)NLM313397090 | ||
| 035 | |a (NLM)32764665 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guo, Chuang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.08.2020 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Several studies show that the immunosuppressive drugs targeting the interleukin-6 (IL-6) receptor, including tocilizumab, ameliorate lethal inflammatory responses in COVID-19 patients infected with SARS-CoV-2. Here, by employing single-cell analysis of the immune cell composition of two severe-stage COVID-19 patients prior to and following tocilizumab-induced remission, we identify a monocyte subpopulation that contributes to the inflammatory cytokine storms. Furthermore, although tocilizumab treatment attenuates the inflammation, immune cells, including plasma B cells and CD8+ T cells, still exhibit robust humoral and cellular antiviral immune responses. Thus, in addition to providing a high-dimensional dataset on the immune cell distribution at multiple stages of the COVID-19, our work also provides insights into the therapeutic effects of tocilizumab, and identifies potential target cell populations for treating COVID-19-related cytokine storms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a IL6R protein, human |2 NLM | |
| 650 | 7 | |a Receptors, Interleukin-6 |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Li, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Huan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaofang |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Pengfei |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Qiaoni |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Liying |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Jingwen |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Zong, Dandan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Yichen |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Kun |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Xuyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Binqing |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Lianxin |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xiaoling |e verfasserin |4 aut | |
| 700 | 1 | |a Weng, Jianping |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Haiming |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Tengchuan |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Qu, Kun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 11(2020), 1 vom: 06. Aug., Seite 3924 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g number:1 |g day:06 |g month:08 |g pages:3924 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-020-17834-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |e 1 |b 06 |c 08 |h 3924 | ||